StrongDecrease
BMI
Liraglutide, Dapagliflozin, and Metformin → BMI
Liraglutide, Dapagliflozin, and Metformin → BMI
Evidence profile
StrongDecreaseWeight & Anthropometrics
Unlock full evidence details
Research Summary
Analyzed using Evidence Intelligence™
Pharmacotherapy may achieve diabetes remission
Key finding
4 out of 14 patients (28.57%) in the intervention arm were in remission.
This study evaluated the effectiveness of pharmacotherapy for achieving diabetes remission. It found that both intervention and control groups had patients in remission, with notable weight loss in the intervention group.
Evidence strength
Moderate confidence
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Some Concerns bias
Last updated July 4, 2026Quick read
Study at a glance
The essential study design details in one scan.
Population
Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes
Intervention
Liraglutide, Dapagliflozin, and Metformin, Vildagliptin, Glimepiride, and Metformin
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Primary outcome
Remission of diabetes
Comparator
Vildagliptin, Glimepiride, and Metformin
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
This study evaluated the effectiveness of pharmacotherapy for achieving diabetes remission. It found that both intervention and control groups had patients in remission, with notable weight loss in the intervention group.
Clinical relevance
Achieving diabetes remission can significantly improve patients' quality of life and reduce the risk of diabetes-related complications. Understanding which pharmacotherapy options are effective can guide clinicians in providing better treatment strategies for their patients.
Keep in mind
Small sample size may limit generalizability. Short duration of follow-up may not capture long-term effects. Potential confounding factors not fully controlled.
Published in
Journal Reference
Publication details and source links for this paper.
Anand S, Durairaj A, Shobhit B, et al. Pharmacotherapy targeting tight glycaemic control is effective in achieving diabetes remission. Indian Journal of Endocrinology and Metabolism. 2025;29(2):217-223. doi:10.4103/ijem.ijem_356_24
Save this study and add notes to your research library.
Main Effects
28.57% of participants in the intervention arm achieved diabetes remission.
Weight loss of 4.7 kg was observed in the intervention arm.
BMI decreased by -1.58 kg/m² in the intervention arm.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Liraglutide, Dapagliflozin, and Metformin, Metformin + glimepiride and BMI, Body fat mass, Body fat percentage reduction, and 4 more.
This study contributes evidence to
Primary intervention
Liraglutide, Dapagliflozin, and Metformin
Primary outcomes
- BMI
- Body fat mass
- Body fat percentage reduction
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
14
Evidence pairs
14
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
3
Related topics
14
Evidence pairs
113
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 14 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Core evidence
Study findings
The primary outcomes reported in this study.
StrongDecrease
Body fat mass
Liraglutide, Dapagliflozin, and Metformin → Body fat mass
Liraglutide, Dapagliflozin, and Metformin → Body fat mass
Evidence profile
StrongDecreaseWeight & Anthropometrics
Unlock full evidence details
StrongDecrease
Body fat percentage reduction
Liraglutide, Dapagliflozin, and Metformin → Body fat percentage reduction
Liraglutide, Dapagliflozin, and Metformin → Body fat percentage reduction
Evidence profile
StrongDecreaseWeight & Anthropometrics
Unlock full evidence details
StrongDecrease
Body weight
Liraglutide, Dapagliflozin, and Metformin → Body weight
Liraglutide, Dapagliflozin, and Metformin → Body weight
Evidence profile
StrongDecreaseWeight & Anthropometrics
Unlock full evidence details
StrongIncrease
Diabetes remission
Liraglutide, Dapagliflozin, and Metformin → Diabetes remission
Liraglutide, Dapagliflozin, and Metformin → Diabetes remission
Evidence profile
StrongIncreaseGlycemic Control
Unlock full evidence details
NoneNo Change
Disposition Index
Liraglutide, Dapagliflozin, and Metformin → Disposition Index
Liraglutide, Dapagliflozin, and Metformin → Disposition Index
Evidence profile
NoneNo ChangeGlycemic Control
Unlock full evidence details
NoneNo Change
Insulin resistance
Liraglutide, Dapagliflozin, and Metformin → Insulin resistance
Liraglutide, Dapagliflozin, and Metformin → Insulin resistance
Evidence profile
NoneNo ChangeMetabolic Health
Unlock full evidence details
StrongDecrease
BMI
Metformin + glimepiride → BMI
Metformin + glimepiride → BMI
Evidence profile
StrongDecreaseWeight & Anthropometrics
Unlock full evidence details
StrongDecrease
Body fat mass
Metformin + glimepiride → Body fat mass
Metformin + glimepiride → Body fat mass
Evidence profile
StrongDecreaseWeight & Anthropometrics
Unlock full evidence details
StrongDecrease
Body fat percentage reduction
Metformin + glimepiride → Body fat percentage reduction
Metformin + glimepiride → Body fat percentage reduction
Evidence profile
StrongDecreaseWeight & Anthropometrics
Unlock full evidence details
StrongDecrease
Body weight
Metformin + glimepiride → Body weight
Metformin + glimepiride → Body weight
Evidence profile
StrongDecreaseWeight & Anthropometrics
Unlock full evidence details
StrongIncrease
Diabetes remission
Metformin + glimepiride → Diabetes remission
Metformin + glimepiride → Diabetes remission
Evidence profile
StrongIncreaseGlycemic Control
Unlock full evidence details
NoneNo Change
Disposition Index
Metformin + glimepiride → Disposition Index
Metformin + glimepiride → Disposition Index
Evidence profile
NoneNo ChangeGlycemic Control
Unlock full evidence details
NoneNo Change
Insulin resistance
Metformin + glimepiride → Insulin resistance
Metformin + glimepiride → Insulin resistance
Evidence profile
NoneNo ChangeMetabolic Health
Unlock full evidence details
Unlock full evidence analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- 28.57% remission in intervention group versus 33.33% in control group.
- Weight loss of 4.7 kg in intervention group.
- BMI reduction of -1.58 kg/m² in intervention group.
Who this applies to
- Adults with type 2 diabetes.
- Patients seeking pharmacotherapy for diabetes management.
Keep in Mind
- Results may not apply to all diabetes types.
- Further research needed to confirm long-term effectiveness.
- Findings are based on a specific population with defined characteristics.
Between the Lines
- Small sample size may limit generalizability.
- Short duration of follow-up may not capture long-term effects.
- Potential confounding factors not fully controlled.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Already have an account?
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Liraglutide, Dapagliflozin, and Metformin and Body Mass Index, Liraglutide, Dapagliflozin, and Metformin and Body Composition.
Related evidence relationships
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention-outcome relationships.
Included in these evidence collections
Curated evidence collections and hubs this study is part of.
Body Composition Evidence Hub
All studies measuring Body Composition
1 studies
outcome_hubMeasures Body Composition as a key outcome.
Body Mass Index Evidence Hub
All studies measuring Body Mass Index
1 studies
outcome_hubMeasures Body Mass Index as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
1 studies
outcome_hubMeasures Body Weight as a key outcome.
Liraglutide, Dapagliflozin, and Metformin Evidence Hub
All studies on Liraglutide, Dapagliflozin, and Metformin
1 studies
intervention_hubContributes to Liraglutide, Dapagliflozin, and Metformin evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in the evidence archive
Jump to pre-filtered views in the evidence archive.
All studies on Liraglutide, Dapagliflozin, and Metformin and BMI
Intervention: Liraglutide, Dapagliflozin, and MetforminOutcome: BMI
1 results
All studies on Liraglutide, Dapagliflozin, and Metformin and Body fat mass
Intervention: Liraglutide, Dapagliflozin, and MetforminOutcome: Body fat mass
1 results
All studies on Liraglutide, Dapagliflozin, and Metformin
Intervention: Liraglutide, Dapagliflozin, and Metformin
1 results
All studies measuring BMI
Outcome: BMI
1 results
All studies measuring Body fat mass
Outcome: Body fat mass
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Metformin Therapies improve body composition?
Emerging Evidence
Metformin Therapies appears to improve Body Composition.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Body fat mass
EvidenceScore™ Emerging | EvidenceScore™ 51.7 | strong positive | ConsensusScore™ Unclear | 1 study
- 2
Body fat percentage reduction
EvidenceScore™ Emerging | EvidenceScore™ 51.7 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a small number of supporting studies and should be interpreted cautiously.
Limitations
- Only a small number of supporting studies are available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Metformin Therapies affect body mass index?
Emerging Evidence
Metformin Therapies may improve Body Mass Index.
ConsensusScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: The available evidence reports mixed findings.
Ranked evidence signals
- 1
BMI
EvidenceScore™ Emerging | EvidenceScore™ 51.7 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
- Population details are unavailable.
Does Metformin Therapies affect body weight?
Emerging Evidence
Metformin Therapies appears to improve Body Weight.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Emerging | EvidenceScore™ 51.7 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on 3 supporting studies and existing graph evidence signals.
Limitations
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Metformin Therapies improve insulin resistance?
Emerging Evidence
Current evidence does not show a clear benefit of Metformin Therapies for Insulin Resistance.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Insulin resistance
EvidenceScore™ Limited | EvidenceScore™ 34.2 | neutral | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on 3 supporting studies and existing graph evidence signals.
Limitations
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in archive
Open broader archive views for this relationship.
Related research
Read related research summaries.
Newer diabetes drugs show stronger weight and blood sugar benefits in prediabetesMediterranean ketogenic eating matched VLCKD for weight loss over 3 monthsLifestyle calorie-carbohydrate plans improved type 2 diabetes remission versus usual careDietary supplements may lower diabetes risk in prediabetesDigital intervention improves glycemic control in type 2 diabetes patients
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.